DEPLOYDatabase

Company

Dexcom

Dexcom is an American multinational medical device company pioneering continuous glucose monitoring (CGM) systems for diabetes management.

Founded
1999
HQ
San Diego, California, USA
Status
public (NASDAQ: DXCM)

The verified answer

As of Aug 2026, DEPLOY verifies Dexcom: 1 model, 2 deployments across 2 regions, $50.0M raised. 3 sources back the record.

Regulatory status2 FDA 510(k) clearances

Dexcom holds 2 FDA 510(k) clearances, per the DEPLOY registry.

See all 2 filings

CategoryBiometric wearables

Overview

Dexcom is an American multinational medical device company pioneering continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, the company's product line includes the Dexcom G6, G7, and Stelo glucose biosensors, with manufacturing facilities in Arizona, Malaysia, and Ireland. Dexcom is publicly traded on Nasdaq (DXCM) and is a component of the S&P 500 and Nasdaq-100.

Verified record

Verified deployments
2 deployments on file
Active incidents
None on file

Valuation of record

DEPLOY VERIFIED
$500M (reported, approximate)as of Jan 2005

Priced roundIPO post-money

See the full valuations ranking →

Key facts

Product

Stelo OTC continuous glucose monitor

Boundary

Glucose-biometric + real AI -> in-definition INCLUDE (not a bare sensor).

CEO

Jacob (Jake) Leach

Listed on

Founders

Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, Bret Megargel

Employees

11,100 (2025)

Revenue

$4.6B (2025 est), $5.16-5.25B guidance for 2026 (11-13% growth)

Data & sources

Press releases

2

News coverage

1

3 sources backing this record.View all →

Current platform

Stelo

Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary include because glucose is in the biometric definition and Stelo pairs an FDA-cleared sensor with a genuine generative-AI insight layer rather than being a bare sensor readout. Made by DexCom (NASDAQ: DXCM) as a product line separate from its prescription G7 monitors, Stelo is the first-ever FDA-cleared over-the-counter, no-prescription continuous glucose biosensor, cleared via De Novo announced on March 5, 2024 and launched in the US on August 26, 2024 for adults 18 and older who are not on insulin, including people with type 2 diabetes not on insulin and non-diabetic users tracking the impact of diet and exercise, with a 15-day wear and no low-glucose alerts since it is not cleared for problematic hypoglycemia. Its AI augmentation is genuine: Dexcom launched a generative-AI platform for Stelo on Google Cloud's Vertex AI and Gemini, providing personalized Weekly Insights, AI photo meal logging, and up to three personalized daily recommendations drawn from glucose, activity, nutrition, and sleep, which is what tips it from a medical sensor to an in-definition biometric-AI device and fills the glucose cell distinct from the heart-rate and sleep watches and rings. Its FDA clearance makes it the strongest verification anchor of the Wave-2 set, while the marketing claim of being the first generative-AI platform in glucose biosensing is not load-bearing and is not asserted, and its exclusion of low-glucose alerting is recorded as an indication boundary.

biometricView model →

Dexcom on the deployment map

View the global map

2 verified deployments across 2 regions, newest verified Jul 2026. Explore where Dexcom's robots are operating, by place and type.

Free to use on your site, with a link back to DEPLOY.

View the full Dexcom deployment record →

Free to use on your site, with a link back to DEPLOY.

Relationships

Current leadership (3)

Founders (2)

See all founders across the registry →

Safety record

No incidents on record for Dexcom.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operator customers (1)

Recent coverage

Dexcom in third-party press

Peers

35 peers across 1 segment. Every Dexcom competitor derived from shared form-factor and application-domain edges.

wearable(35)

32 companies in this segment · highly_concentrated (HHI 2595.3892239124602) · leader Oculus VR at 4361%